Metraipolis › archive › dc_fa95095aef40

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase… — Europe PMC PMID:42026180

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42026180
DOI: 10.1038/s41375-[numero omesso]-8
License (as archived): solo-consultazione
Archived: 2026-10-08T00:57:43.215Z
SHA-256 of the archived text: 1ea74e60c2a015a17ec2f202ce3dc1f29e86f9993b87f456c97c061301bbcd2d
Stable URL of this page: https://metraipolis.com/documento/dc_fa95095aef40

How to cite

ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase… — Europe PMC PMID:42026180 — Europe PMC (en), https://europepmc.org/article/MED/42026180 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa95095aef40 (Metraipolis archive dc_fa95095aef40, sha256 1ea74e60c2a015a17ec2f202ce3dc1f29e86f9993b87f456c97c061301bbcd2d)

BibTeX

@misc{dcfa95095aef40,
  title = {ASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase… — Europe PMC PMID:42026180},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42026180},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa95095aef40; sha256 1ea74e60c2a015a17ec2f202ce3dc1f29e86f9993b87f456c97c061301bbcd2d},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42026180. Agents can read the archived copy with the MCP tool read_document.